Tag: statements

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

Châtillon, France, June 8, 2026

BRADENTON, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (Nasdaq: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Ashlee Weisser to Chief Financial Officer effective June 8, 2026. She succeeds Mel Hope, who announced his planned retirement earlier this year and will continue to serve in an Advisor role to support a seamless leadership transition.

Acquisition of Calavo Growers completed May 28, 2026

First Quarter Revenue Grows 50% to $52.8 Million; Net Income Increases 66% to $2.1 Million with Adjusted EBITDA Up 71% to $4.9 Million; Cash Position Grows to $24.4 Million

FLOWER MOUND, Texas, June 08, 2026 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX) announces that on June 3, 2026, Yasir Haider was appointed Chief Financial Officer of Mannatech, Incorporated (the "Company").

Did you buy SRAD Class A ordinary shares between November 7, 2024, and April 21, 2026?

ZUG, Switzerland, June 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the 47^th Annual Goldman Sachs Global Healthcare Conference.  

New York, NY, June 08, 2026 (GLOBE NEWSWIRE) -- FutureCorp Space Acquisition 1 (the “Company”) announced today the closing of its initial public offering of 23,000,000 units, which includes 3,000,000 units issued pursuant to the exercise by the underwriters of their over-allotment option in full. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000. The Company’s units began trading on June 5, 2026 on The New York Stock Exchange (“NYSE”) under the ticker symbol “FTRAU.” Each unit consists of one Class A ordinary share of the Company and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share of the Company at an exercise price of $11.50 per share, subject to certain adjustment. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on NYSE under the symbols “FTRA” and “FTRAW,” respectively. Of the proceeds received from the consummation of the initial public offering (including the exercise of the over-allotment option) and a simultaneous private placement of warrants, $230,000,000 (or $10.00 per unit sold in the offering) was placed in trust.